MiMedx Group, Inc (MDXG): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDXG Stock Price Chart Interactive Chart >
MDXG Price/Volume Stats
|Current price||$11.03||52-week high||$12.87|
|Prev. close||$10.76||52-week low||$3.38|
|Day high||$11.06||Avg. volume||546,389|
|50-day MA||$10.59||Dividend yield||N/A|
|200-day MA||$8.61||Market Cap||1.23B|
MiMedx Group, Inc (MDXG) Company Bio
MiMedx Group developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. The company was founded in 2008 and is based in Marietta, Georgia.
MDXG Latest News Stream
|Loading, please wait...|
MDXG Latest Social Stream
View Full MDXG Social Stream
Latest MDXG News From Around the Web
Below are the latest news stories about Mimedx Group Inc that investors may wish to consider to help them evaluate MDXG as an investment opportunity.
Availability of EPIFIX Allografts Expected Early 2022 Approval Makes it Possible to Bring EPIFIX’s Healing Properties to as Many as 100,000 New Patients Annually MARIETTA, Ga., June 08, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced successful regulatory approval by the Japanese Ministry of Health, Labour and Welfare (JMHLW) to market EPIFIX® in Japan.
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2021 Annual Meeting of Shareholders
Deadline to Pre-Register Extended to May 26, 2021 at 10:00 a.m. Eastern Pre-Registration Required to Attend Annual Meeting Visit www.votemimedx.com for Instructions on How to Pre-Register MARIETTA, Ga., May 25, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today reminded shareholders to pre-register for the upcoming 2021 Annual Meeting of Shareholders (“Annual Meeting”), by no later than 10:00 a.m. Eastern on Wednesday, May 26, 2021. In order to attend the virtual meeting, all MIMEDX shareholders of record must pre-register by the extended deadline of 10:00 a.m. Eastern on May 26, 2021. Instructions on how to pre-register can be found within the Company’s 20...
Vote FOR MIMEDX’s Experienced and Highly Qualified Directors and Governance Enhancement Proposals MARIETTA, Ga., May 12, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today reminded shareholders to vote at the upcoming 2021 Annual Meeting of Shareholders (“Annual Meeting”), which will be held on May 27, 2021. MIMEDX’s Board of Directors unanimously recommends that shareholders vote FOR all four of its director nominees and FOR all proposals on the Company’s WHITE proxy card. MIMEDX has also confirmed that Prescience Point has voluntarily withdrawn its proxy contest and its proposed director candidates. MIMEDX has four deeply experienced and highly qualified ...
Prescience Point Capital Management ("Prescience Point"), a research-focused, catalyst-driven investment firm that is the beneficial owner of approximately 8.1% of the outstanding shares of MiMedx Group, Inc. (NASDAQ: MDXG) ("MiMedx" or the "Company"), today announced that it has withdrawn its slate of nominees for election to the Board of Directors at the Annual Meeting of Shareholders (the "Annual Meeting"), scheduled to be held on May 27, 2021.
MIMEDX Urges Shareholders to Consider Prescience Point’s Motivations Before Voting Their Shares at the Company’s Annual Meeting
SELECT HISTORICAL PURCHASES AND SALES OF MIMEDX STOCK BY PRESCIENCE POINT In its Proxy statement, Prescience Point takes credit for the stock price increase following the publication of its promotional “report” but neglects to disclose its subsequent stock sales at a higher price. Questions Every Shareholder Should Ask Prescience Point Prescience Point’s Trading History Tells the Real Story MARIETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today urged shareholders to consider several key questions about Prescience Point’s interests, motivations and actions regarding the disruptive proxy fight it is waging to gain undue influence over the M...
MDXG Price Returns